Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Vanda Pharmaceuticals Announces Availability of HETLIOZ(TM) (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)
PR Newswire - Wed Apr 09, 6:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.
Vanda Pharmaceuticals Shares Up 22.5% Since SmarTrend's Buy Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 08, 11:10AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 22.53% as of today's recent price of $15.31.
Vanda Pharmaceuticals Has Returned 33.8% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 01, 9:43AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 33.81% as of today's recent price of $16.72.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 26, 12:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
41.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Tue Mar 25, 9:18AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 41.74% as of today's recent price of $17.71.
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 3:25PM CDT
You might be compelled to think that territorial tensions between Russia and Ukraine and generally mixed economic data might push the market lower, but you'd be sorely mistaken. In fact, new highs are outpacing new lows by close to a 10-to-1 margin...
Breakfast Round-up - 52-Weeks High Reset: NextEra Energy, Silver Standard Resources, Wisconsin Energy, and Vanda Pharma
PR Newswire - Tue Mar 18, 8:39AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1,858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include NextEra Energy Inc. (NYSE:NEE), Silver Standard Resources Inc. (NASDAQ:SSRI), Wisconsin Energy Corporation (NYSE MKT: WEC), and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Free research on these four companies can be accessed at:
Vanda Pharmaceuticals Up 44.3% Since SmarTrend Uptrend Call (VNDA)
Comtex SmarTrend(R) - Mon Mar 17, 5:19PM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 44.30% as of today's recent price of $18.03.
Vanda Pharmaceuticals (VNDA) Soars: Stock Adds 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:21AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) was a big mover last session, as the company saw its shares rise by roughly 10% on the day.
Vanda Pharmaceuticals Has Returned 21.1% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Mon Mar 10, 11:11AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 21.09% as of today's recent price of $15.13.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Shares of VNDA Up 20.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 03, 9:51AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 20.61% as of today's recent price of $15.07.
Blind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder
PR Newswire - Fri Feb 28, 6:00AM CST
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at Non-24.com. This national education initiative aims to raise awareness for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious, chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.[1]
5 Monster Momentum Stocks to Trade
at The Street - Tue Feb 25, 1:23PM CST
Momentum traders and trend-following traders are basking in profits in this current market.
10-K: VANDA PHARMACEUTICALS INC.
Edgar Online - Tue Feb 25, 6:04AM CST
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS